Nothing found
Sus Clinicals Welcomes New CEO
Effective August 1, 2024, Jessicca M. Rege, Ph.D. joins Sus Clinicals as CEO.
Dr. Rege brings deep scientific expertise and a demonstrated track record of cross-functional business and scientific leadership, from start-ups to major global pharmaceutical players.
“I am thrilled to be joining the Sus Clinicals team,” said Dr. Rege. “My passion is to accelerate transformative research and therapeutics into the clinic, with the hope to save lives.β― To bring the qualified and FDA cleared Oncopig® platform to more researchers is a wonderful opportunity professionally and for the patients we all serve.”
Most recently Dr. Rege was Chief Development Officer of Mural Oncology. Prior to Mural she served as VP, Head of Clinical Development, Oncology at Alkermes. Over her career she has held multiple leadership roles in larger pharmaceuticals companies, all with significant oncology portfolios, including Daiichi-Sankyo, Eli Lilly and Eisai Inc., to name a few.
“Dr. Rege’s educational background, her extensive pharmaceuticals experience, and her superb leadership skills all position her well to take Sus Clinicals to the next level,” said Jeff Weedman, Board Chair and Co-Founder of the Company.